MOTS-C

What if a signal your own mitochondria already sends could be replicated in a lab and prescribed as a treatment, and what would it mean if the science isn't there yet to support that? At Belle, we are a 100% online telehealth platform with employed doctors and nurses so patients can speak directly with a licensed clinician, and every prescription is reviewed by a US-licensed provider. In this piece, we cover what MOTS-C is, what the research actually shows, what the FDA has flagged, and the questions worth asking before considering any peptide.

What Is MOTS-C?

MOTS-C stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a 16-amino-acid MOTS-C peptide encoded within mitochondrial DNA, first described in 2015 by a research team that reported it regulates insulin sensitivity and metabolic balance, with skeletal muscle as its primary target tissue.

The idea that mitochondria do more than make energy, and actually send signals through small peptides, is what makes MOTS-C scientifically interesting. The compounded product sold under the same name is a synthetic version of that naturally occurring peptide.

Why People Are Interested in MOTS-C Therapy

Most searches for MOTS-C therapy come from three places:

• Energy and exercise capacity
• Metabolic health and insulin sensitivity
• Longevity or healthy aging support

What the animal research shows

The rationale comes largely from mouse studies. The 2015 study reported that MOTS-C treatment in mice prevented age-related and high-fat-diet-induced insulin resistance and diet-induced obesity. A 2019 follow-up using metabolomics in diet-induced obese mice reported changes in plasma metabolite pathways linked to metabolic dysfunction. A 2021 study described MOTS-C as an exercise-induced regulator of age-dependent physical decline in muscle research.

What the human research shows

Human evidence is much thinner. One small study measured naturally circulating MOTS-C in 10 lean and 10 obese adults and found that plasma levels correlated with insulin sensitivity measures in the lean group but not the obese group. It did not give anyone MOTS-C as a treatment.

That difference matters. Measuring a peptide the body already makes is not the same as proving that injecting it is safe or effective. No published studies have examined the effects of MOTS-C injections in people.

What the FDA Has Flagged About MOTS-C

In July 2026 briefing materials for its Pharmacy Compounding Advisory Committee, FDA reviewers addressed MOTS-C directly. Their key points:

Neither MOTS-C free base nor MOTS-C acetate is a component of an FDA-approved drug, and there is no USP or NF monograph for either form.

"MOTS-C" is a common name, not a United States Adopted Name, and inconsistent naming creates a risk that patients receive a different substance than the one ordered.

A search of published literature did not reveal studies in which compounded drug products containing MOTS-C were used in humans, so potential safety risks in people are unknown.

As a 16-amino-acid peptide given by injection, MOTS-C may carry immunogenicity risk, especially if aggregates or impurities form during manufacturing or storage.

Taken together, the evaluation criteria weighed against adding MOTS-C to the list of bulk substances allowed for compounding under section 503A.

For a patient, this translates to practical questions: who is making the product, what exactly is in it, what evidence supports its use, and who is responsible for monitoring safety?

How We Approach Peptides at Belle

If MOTS-C brought you into longevity research, it helps to see how supervised peptide care is structured. Our longevity treatments overview explains that every prescription product requires a consultation with a licensed provider who determines whether treatment is appropriate for you.

Our Sermorelin page shows what we think a peptide listing should look like: prescription required, available only after a licensed provider reviews your medical history, and a clear notice that the compounded product is not FDA-approved. Our NAD+ page follows the same structure, with eligibility screening and an important notice about compounded medications.

Those pages are not interchangeable with MOTS-C and should not be read as evidence that MOTS-C is right for you. They are the standard to hold any peptide offer against: individualized review, honest safety language, and no guaranteed results.

Safety Questions to Bring to a Clinician

Before considering any peptide, ask a licensed clinician:

• Is this supported by human clinical evidence for my goal?
• What is known from animal studies, and what remains unknown in people?
• Is this an FDA-approved drug, a compounded medication, or something else?
• What quality controls apply to the specific product?
• What monitoring would be appropriate for my health history?
• What should I do if side effects occur?

If you experience side effects, contact your care team. In an emergency, call 911 or go to the nearest emergency room — do not wait for a chat response.

Talk With Belle Before You Decide

MOTS-C is worth discussing carefully, not casually. Our clinicians can review your health history, walk through what the research does and does not support, and discuss which longevity options, if any, make sense for you. A consultation is a conversation with a licensed provider, not a promise of any particular prescription. Book a consultation when you are ready.

Disclaimer:

Compounded medications are not evaluated or approved by the FDA. This means the FDA does not assess them for safety, effectiveness, or quality. This content is for educational purposes only and is not intended to diagnose, treat, or replace personalized medical advice. It is not a substitute for medical advice from your care team. Always talk with your provider about your treatment. Compounded medications are not FDA-evaluated for safety or effectiveness. GLP-1 medications are not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Not suitable for type 1 diabetes. Results may vary. All prescriptions are issued by licensed healthcare providers. Belle Health is not a pharmacy. This information is not medical advice.

Sources:

1. Lee, C., Zeng, J., Drew, B. G., Sallam, T., Martin-Montalvo, A., Wan, J., Kim, S. J., Mehta, H., Hevener, A. L., de Cabo, R., & Cohen, P. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454. https://doi.org/10.1016/j.cmet.2015.02.009
2. Kim, S. J., Miller, B., Mehta, H. H., Xiao, J., Wan, J., Arpawong, T. E., Yen, K., & Cohen, P. (2019). The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports, 7(13), Article e14171. https://doi.org/10.14814/phy2.14171
3. Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., Joly, J. H., Mitchell, C. J., Cameron-Smith, D., Lu, R., Cohen, P., Graham, N. A., Benayoun, B. A., Merry, T. L., & Lee, C. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12(1), Article 470. https://doi.org/10.1038/s41467-020-20790-0
4. Cataldo, L. R., Fernández-Verdejo, R., Santos, J. L., & Galgani, J. E. (2018). Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. Journal of Investigative Medicine, 66(6), 1019–1022. https://doi.org/10.1136/jim-2017-000681
5. U.S. Food and Drug Administration. (2026, July). MOTS-c-related bulk drug substances [Pharmacy Compounding Advisory Committee briefing document]. https://www.fda.gov/media/193347/download